NGC Update Service: October 24, 2016 || National Institute for Health and Care Excellence (NICE)

NGC Update Service: October 24, 2016

National Institute for Health and Care Excellence (NICE)

• Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes.
• Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer. This updates a previously published guideline summary.